Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — Investor Presentation (January 2026)
17 slides from Enveric Biosciences's investor presentation, Jan 9, 2026
Slide 1: Corporate Presentation Q1 2026
pl Nasdaq:ENVB a” ENVER IC ™ temarecien= BrI"O-S<C ISHN CES CORPORATE PRESENTATION Q1 2026 Enveric.com
Slide 2: Disclaimer
Disclaimer XG Offer or Sol S nis communi nal purposes only and is net intended to and does not constitute an offer of the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It d constitute a prospectus or prospectus equivalent document. No offering of securitie
Slide 3: Next Generation Mental Health
Slide 4: Significant Global Health Issues: Depression, Anxiety & PTSD
Significant Global Health Issues: Depression, Anxiety & PTSD 65 million in the US ey) 40% 1 billion globally Experience a neuropsychiatric First line SSRI treatments work disorder at some time in their lives for less than half of patients Recent Discovery: Mental health disorders are associated with
Slide 5: Neuroplastogens: A New Class of Drugs
Neuroplastogens: A New Class of Drugs Prefrontal Cortex Healthy Brain: Neurons in the prefrontal cortex (PFC) regulate emotional behavior via Top-Down control of the amygdala. Neuroplastogens stimulate neuroplasticity in the PFC, which restores it to normal function and rescues the Neuropsychiatric
Slide 6: Psychedelic Neuroplastogen Drawbacks
Psychedelic Neuroplastogen Drawbacks: * Current psychedelic neuroplastogens in clinical trials cause hallucinations in the patient * Can require 8 hrs in-clinic treatment with two healthcare providers present, plus pre and post treatment counselling * Often require psychotherapy as part of the treat
Slide 7: EB-003: First-in-Class Dual 5-HT2A and 5-HT1B Agonist
Ja nasdag:ENve EB-00O3: First-in-Class: Dual 5-HT2A partial agonist & 5-HTIB Agonist Non-Hallucinogenic, Orally Available 5-HT2A * partial agonism reported to stimulate neuroplasticity in prefrontal cortex (PFC) * responsible for higher-level cognition decision-making and social behavior 5-HT1B * ag
Slide 8: Big Pharma Validation of Neuroplastogen Hypothesis
Big Pharma Validation of Neuroplastogen Hypothesis 5-HT2A Receptor Agonists Induce Neuroplasticity Recent deals demonstrate Big Pharma’s appetite for 5-HT2A candidates , $1.9B option to license GILGAMESH | abobvie $1.2B acquisition of bretisilocin $60M+ acquisition Mindset | @ onukc Pharma Vasdag:EN
Slide 9: Commercially Proven 5-HT1B/1D Receptor Target
Commercially Proven 5-HTIB/ID Receptor Target 5-HTI1B/ID: Proven safe and effective for migraine in millions of patients by Triptan class of drugs TRIPTAN ¢ Simatriptan i © (Imitrex) ¢ Rizatriptan o (Maxalt) 2. Z oleate Well defined safety and efficacy profile: 2 (Zomig) >100M patients treated world
Slide 10: EB-003: A New Treatment Standard
EB-003: A New Treatment Standard Psychedelic Targeted Benefits* Antidepressants Neuroplastogens For EB-003 Immediate efficacy CS v Low side effects Vv Treatment in-clinic not required Vv Vv Large patient population VY Vv Induces neuroplasticity in brain Vv Vv *To be proven in human clinical trials P
Slide 11: EB-003 Development
EB-003 Development Target Characteristics o Differentiated mechanism: Dual engagement of 5-HT2A and 5-HTIB receptors oLarge addressable market: Multiple high-burden psychiatric conditions with limited effective treatments eCompelling preclinical profile: Fast-acting, durable, and non-hallucinogenic
Slide 12: EVM401: Lead Discovery Underway
EVM401: Lead Discovery Underway Overview + Novel phenylalkylamines and indolethylamines + Anticipated to interact with key brain receptors associated with mental health disorders and addiction. Potential Applications: + Early analysis suggests EVM401 compounds could target: + Substance use disorders
Slide 13: Market Potential: Redefining the Treatment Landscape
Market Potential: Redefining the Treatment Landscape for Mental Health Disorders Current Approved Antidepressant Market: Global market driven by the rising prevalence of Depression a N of patients experience \ 0 Ff inadequate relief Side Effects & Delayed Onset SSRIs/SNRIs take 4-6 WEEKS weeks to wo
Slide 14: Product Pipeline
Product Pipeline Stage _Partner/Licensee ea Available for Partnering Partner EB-003 & EVM301 Series Neuroplastogens Preclinical EVM401 Series Neuroplastogens Discovery Ou ensed Licensee EB-002 & EVM201 Series Psilocin Prodrugs Preclinical MycoMedica Life Sciences $62 Million Topical Candidates for R
Slide 15: Management
Management Management Team Joseph Tucker, Ph.D. C f Executive Officer Kevin Coveney, CPA Chief Financial Office: Jillian Hagel, Ph.D. 2sident Innovation 4 vasdag:enve Board of Directors Michael D. Webb Board Chair George Kegler Director, Chair of the Audit Committee Frank Pasqualone Director, Chair
Slide 16: Potential First-in-Class Entrant to Large Mental Health Market
Potential First-in-Class Entrant to Large Mental Health Market EB-003: Novel Mechanism Drug Candidate + Anticipate filing IND in Q1 of 2026 and Phase | start in Q2 2026 New Drug Class Market Opportunity + $30B+ market and expected to grow + Existing treatments only reach half the patients, carry sig
Slide 17: Enveric Biosciences
Nasdaq :ENVB ca if ENT EER? tence nea BIOSCIENCES Enveric.com
Enveric Biosciences — Investor Presentation (January 2026) on 6ix